Join
AVROBIO Inc. logo

AVRO

NASDAQ

AVROBIO Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2018
$1.40-0.02 (-1.41%)
News25/Ratings9

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest news

25 items

AVRO FAQ

7 questions
  • What does AVROBIO Inc. do?
    AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing...
  • Where does AVRO stock trade?
    AVROBIO Inc. (AVRO) is listed on NASDAQ.
  • What sector and industry is AVRO in?
    AVROBIO Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did AVROBIO Inc. go public?
    AVROBIO Inc. (AVRO) completed its IPO in 2018.
  • What are analysts saying about AVRO?
    AVROBIO Inc. has had 8 recent analyst actions on file. The most recent action was from Mizuho: Neutral on 2023-12-18.
  • What companies are similar to AVRO?
    Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare AVRO side-by-side with any of them on Quantisnow.
  • How can I track AVRO on Quantisnow?
    Quantisnow aggregates AVROBIO Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVRO to receive live email and push alerts on every new disclosure.